Israel - English - Ministry of Health

teva israel ltd - spironolactone - tablets - spironolactone 100 mg - spironolactone - spironolactone - edematous conditions: congestive heart failure; cirrosis of the liver accompanied by edema and/or ascites nephrotic syndrome. essential hypertention. primary hyperaldostronism. hypokalemia.

Kenya - English - Pharmacy and Poisons Board

lords healthcare limited ground floor capitol hill towers cathedral road - iron 50mg folic acid 500mcg cyanocobalamin 6mcg… - suspension and effervescent granules for oral - iron 50mg folic acid 500mcg cyanocobalamin 6mcg… - antianemic preparations - iron preparations: iron

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron (iii) - solution for injection/infusion - 20 milligram(s)/millilitre - iron trivalent, oral preparations; saccharated iron oxide

Ireland - English - HPRA (Health Products Regulatory Authority)

vifor france - iron (iii) - hydroxide sucrose complex - solution for injection/infusion - 20  milligram(s)/millilitre - iron trivalent, oral preparations; saccharated iron oxide

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

inca (flight) co pty ltd - cobalt as cobaltous sulfate heptahydrate; copper present as copper sulfate pentahydrate; iron as ferric ammonium citrate, ferrous gluconate, ferr; manganese as manganese sulfate monohydrate - oral solution/suspension - cobalt as cobaltous sulfate heptahydrate mineral-cobalt active 0.2 mg/l; copper present as copper sulfate pentahydrate mineral-copper active 14.7 mg/l; iron as ferric ammonium citrate, ferrous gluconate, ferr mineral-iron active 16.0 g/l; manganese as manganese sulfate monohydrate mineral-manganese active 14.9 mg/l - nutrition & metabolism - dog - greyhound | horse | colt | donkey | endurance horse | filly | foal | gelding | high performance horses | horses at stud | - iron supplement

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - buspirone hydrochloride 10mg - tablet - 10 mg - active: buspirone hydrochloride 10mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - buspirone hydrochloride is indicated for the management of anxiety with or without accompanying depression in adults. buspirone hydrochloride is indicated for the management of anxiety disorders or the short-term relief of symptoms of anxiety with or without accompanying depression.

New Zealand - English - Medsafe (Medicines Safety Authority)

orion pharma (nz) limited - buspirone hydrochloride 5mg - tablet - 5 mg - active: buspirone hydrochloride 5mg excipient: colloidal silicon dioxide lactose monohydrate magnesium stearate microcrystalline cellulose sodium starch glycolate - buspirone hydrochloride is indicated for the management of anxiety with or without accompanying depression in adults. buspirone hydrochloride is indicated for the management of anxiety disorders or the short-term relief of symptoms of anxiety with or without accompanying depression.

United States - English - NLM (National Library of Medicine)

redpharm drug, inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 5 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual du

United States - English - NLM (National Library of Medicine)

preferred pharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 15 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d

United States - English - NLM (National Library of Medicine)

preferredpharmaceuticals inc. - buspirone hydrochloride (unii: 207lt9j9oc) (buspirone - unii:tk65wks8hl) - buspirone hydrochloride 10 mg - buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the efficacy of buspirone hydrochloride tablets have been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to generalized anxiety disorder (gad). many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. the patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. generalized anxiety disorder (300.02) is described in the american psychiatric association’s diagnostic and statistical manual, iii1 as follows: generalized, persistent anxiety (of at least 1 month continual d